CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 146 enrolled
Drug / intervention
bevacizumab [Avastin] +1 moredrug
Likely dose
bevacizumab [Avastin] 10mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00796757
NCT00796757Phase 2Completed
CompareCT.gov

An Open Label Study of the Effect of First Line Treatment With Avastin (Bevacizumab) in Combination With Low-dose Interferon on Progression-free Survival in Patients With Metastatic Clear Cell Renal Cell Carcinoma.

Hoffmann-La Roche·interventional·Posted Nov 24, 2008·Updated May 27, 2015

In Brief

A Phase 2 clinical trial evaluating bevacizumab [Avastin] and interferon alfa-2a for Renal Cell Cancer. Completed, enrolled 146 participants across 50 sites in 12 countries.

Detailed Summary

This single arm study will assess progression free survival, tumor response and safety of Avastin in combination with interferon alfa-2a (IFN) as first line treatment in patients with metastatic clear cell renal cell carcinoma. Patients will receive Avastin (10mg/kg iv) every 2 weeks in combination with a low dose of interferon alfa-2a (3 MIU sc three times per week (t.i.w.). The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Cancer
CountriesCzechia, Estonia, Finland, Germany, Greece, Italy, Lithuania, Netherlands, Russia, Sweden, Switzerland, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 24, 2008
Enrollment StartDec 1, 2008
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 17.6 years ago

Interventions

bevacizumab [Avastin]drug

10mg/kg iv infusion every 2 weeks

interferon alfa-2adrug

3 MIU sc t.i.w.